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Abstract
BACKGROUND—The use of adjuvant chemotherapy in patients with breast cancer may be 
guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of 
recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic 
information to the recurrence score is not known.
METHODS—We performed a prospective trial involving 9427 women with hormone-receptor–
positive, human epidermal growth factor receptor 2–negative, axillary node–negative breast 
cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of 
recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The 
effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use 
of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the 
majority of the premenopausal women who were 50 years of age or younger.
RESULTS—The level of clinical risk was prognostic of distant recurrence in women with an 
intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores 
indicating a worse prognosis or a greater potential benefit from chemotherapy) who were 
randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low clinical 
risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus endocrine 
(chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in women with a high 
recurrence score (a score of 26 to 100), all of whom were assigned to chemoendocrine therapy 
(hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who were 50 years of age or younger 
who had received endocrine therapy alone, the estimated (±SE) rate of distant recurrence at 9 
years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective 
of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this 
age group, the estimated distant recurrence at 9 years exceeded 10% among women with a high 
clinical risk and an intermediate recurrence score who received endocrine therapy alone 
(12.3±2.4%) and among those with a high recurrence score who received chemoendocrine therapy 
(15.2±3.3%).
CONCLUSIONS—Clinical-risk stratification provided prognostic information that, when added 
to the 21-gene recurrence score, could be used to identify premenopausal women who could 
benefit from more effective therapy. (Funded by the National Cancer Institute and others; 
ClinicalTrials.gov number, .)
CLINICOPATHOLOGICAL FEATURES, INcluding tumor size, histologic grade, and the 
presence of axillary lymph-node metastases, provide prognostic information about disease 
recurrence in women who have localized breast cancer after surgery, but these features have 
not been shown to be predictive of benefit from adjuvant chemotherapy.1 In women with 
hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative 
early breast cancer, the 21-gene recurrence-score assay provides prognostic information that 
is independent of clinicopathological features,2 and a high score (on a scale of 0 to 100) 
indicates a higher rate of distant recurrence and is predictive of chemotherapy benefit. A 
high score has been defined as 31 or higher on the basis of the prospective validation 
National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 and Southwest 
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Oncology Group S8814 trial cohorts3,4 or 26 or higher on the basis of the NSABP B20 trial 
cohort.5,6
The prospective Trial Assigning Individualized Options for Treatment (TAILORx) showed 
that endocrine therapy alone was noninferior to adjuvant chemotherapy plus endocrine 
(chemoendo-crine) therapy in women with hormone-receptor–positive, HER2-negative, 
axillary node–negative breast cancer and a 21-gene recurrence score of 11 to 25. An 
exploratory analysis indicated some benefit of chemotherapy in women 50 years of age or 
younger who had a recurrence score of 16 to 25. The trial also showed a low percentage of 
women with distant recurrence (3%) at 9 years with endocrine therapy alone if the 
recurrence score was 0 to 15, irrespective of age.7,8
Here, we report the results of secondary analyses of the TAILORx trial that were designed to 
determine whether clinical risk, as assessed with the use of an algorithm that integrates 
tumor size and histologic grade, adds prognostic information to the 21-gene recurrence score 
and predictive information regarding the benefit of chemotherapy. We further examined the 
relationship between age and the absolute chemotherapy benefit in women who were 50 
years of age or younger and had a recurrence score of 16 to 25.
METHODS
TRIAL DESIGN AND PATIENTS
TAILORx, a prospective clinical trial, was sponsored by the National Cancer Institute and 
was coordinated by the Eastern Cooperative Oncology Group–American College of 
Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group, as previously 
described.7 Women who participated in the trial provided written informed consent, 
including a statement of willingness to have treatment assigned or randomly assigned on the 
basis of the 21-gene Oncotype DX recurrence-score assay performed in a central laboratory 
(Genomic Health).2
OBJECTIVE AND DEFINITION OF CLINICAL RISK
The standardized definitions for efficacy end points (STEEP) criteria were used for end-
point definitions.9 One end point was the distant recurrence–free interval, referred to here as 
distant recurrence (defined as the time from registration to the date of distant recurrence of 
breast cancer, or of death with distant recurrence, if death was the first manifestation of 
distant recurrence). Another end point was invasive disease–free survival, defined as the time 
from registration to the first event of recurrence (distant or locoregional), second primary 
cancer (excluding nonmelanoma skin cancers), or death without evidence of recurrence.
A prespecified secondary trial objective was to determine whether clinical risk, as assessed 
with the use of the Adjuvant! algorithm, added information regarding prognosis for 
recurrence and prediction of chemotherapy benefit to that projected by the Oncotype DX 
test.7 Classic pathologic information and outcome results were also used to refine models 
based on classic information and genomic tests. Adjuvant! is a tool that uses 
clinicopathological characteristics to provide estimates of breast cancer outcomes at 10 years 
on the basis of the Surveillance, Epidemiology, and End Results registry data and treatment 
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effects associated with adjuvant chemotherapy and endocrine therapy derived by the Early 
Breast Cancer Trialists’ Collaborative Group meta-analysis that has been validated in several 
data sets.10,11
Since Adjuvant! is no longer available for clinical use, we assessed the prognostic 
information provided by a binary clinical-risk categorization based on the Adjuvant! 
algorithm as used in the MINDACT (Microarray in Node-Negative Disease May Avoid 
Chemotherapy) trial.12 A low clinical risk was defined as the probability of breast cancer–
specific survival at 10 years without systemic therapy among more than 92% of women with 
estrogen receptor–positive tumors who received endocrine therapy alone, as projected by 
Adjuvant! (version 8.0).11 Clinical risk was defined as low if the tumor was 3 cm in diameter 
or smaller and had a low histologic grade, 2 cm or smaller and had an intermediate grade, or 
1 cm or smaller and had a high grade; the clinical risk was defined as high if the low-risk 
criteria were not met.
OVERSIGHT
This trial was coordinated by the ECOG-ACRIN Cancer Research Group, with other 
federally funded groups participating, including the Southwest Oncology Group, the 
Alliance for Clinical Trials in Oncology, NRG Oncology, and the Canadian Cancer Clinical 
Trials Network.
The statistical analysis was performed by the second author, the manuscript was written by 
the first author, and a final version of the manuscript, incorporating changes recommended 
by the coauthors, was reviewed and approved by all the authors, who vouch for the accuracy 
and completeness of the data and the adherence of the trial to the protocol (available with the 
full text of this article at NEJM.org). No one who is not an author contributed to the 
manuscript. No commercial support was provided in the planning or execution of the trial, 
but commercial support was provided by Genomic Health, the makers of the 21-gene risk 
score tool, for collection of follow-up information from the treatment sites.
STATISTICAL ANALYSIS
This analysis involved the same intention-to-treat population previously described.7 Event-
free rates were estimated with the use of the Kaplan–Meier method, with confidence 
intervals computed with log–log transformation and Greenwood’s variance. Hazard ratios 
were estimated with the use of partial likelihood analysis of the Cox proportional-hazards 
model, with confidence intervals symmetric on the log-ratio scale. No corrections for 
multiple comparisons were made.
RESULTS
CLINICAL-RISK CATEGORY, 21-GENE RECURRENCE SCORE, AND AGE
The trial was conducted from April 2006 to October 2010. Of the 9719 women in the trial 
who were included in the primary intention-to-treat population and who had data that could 
be evaluated, information regarding clinical risk, including both tumor size and histologic 
grade, was available for 9427 (97.0%), of whom 6615 (70.2%) had low clinical risk and 
Sparano et al. Page 5
N Engl J Med. Author manuscript; available in PMC 2019 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2812 (29.8%) had high clinical risk, with a similar distribution according to age (≤50 years 
vs. >50 years). The recurrence score was high (a score of 26 to 100) in 589 patients (8.9%) 
with low clinical risk and in 770 patients (27.4%) with high clinical risk; these distributions 
were also similar according to age. Endocrine therapy administered to women who were 
reported to be premenopausal at registration and to have a recurrence score of 11 or higher 
included tamoxifen in 78% of the women (including 35% who crossed over to an aromatase 
inhibitor) and ovarian function suppression alone or in combination with an aromatase 
inhibitor in 13%; 7% of the women were reported to receive an aromatase inhibitor, which 
could indicate either incorrect reporting of menopausal status at registration or 
chemotherapy-induced menopause.
CLINICAL-RISK CATEGORY AND PROGNOSIS
Prognostic information provided by the clinical-risk category is shown in Figure 1. 
Estimated hazard ratios reflect the comparison of the high clinical-risk group with the low 
clinical-risk group; a hazard ratio greater than 1 indicated that a high clinical risk was 
prognostic for a higher event rate. The clinical-risk category added prognostic information 
regarding distant recurrence in patients who received endocrine therapy alone and who had 
an intermediate recurrence score of 11 to 25 (hazard ratio, 2.73; 95% confidence interval 
[CI], 1.93 to 3.87) and in patients treated with chemoendocrine therapy who had an 
intermediate recurrence score (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) or a high recurrence 
score of 26 to 100 (hazard ratio, 3.17; 95% CI, 1.94 to 5.19).
In a model of distant recurrence incorporating clinical risk and the recurrence score for the 
group of patients with an intermediate recurrence score (6496 patients and 240 distant 
recurrences), significant prognostic information was provided by both the clinical-risk level 
(hazard ratio for high vs. low risk, 2.42; P<0.001) and the continuous recurrence score 
(hazard ratio for an increase of 1 point in the recurrence score, 1.08; 2397 P<0.001). Similar 
findings were noted for rates of invasive disease–free survival events (defined as freedom 
from invasive disease recurrence, second primary cancer, or death).
An evaluation of the effect of clinical risk on prognosis with respect to distant recurrence 
and invasive disease–free survival, stratified according to age, showed similar prognostic 
effects in women older than 50 years of age and in women 50 years of age or younger. 
Weaker associations between clinical risk and distant recurrence were observed in older 
women who had a low recurrence score (a score of 0 to 10) than among those who had a 
higher recurrence score, and no association was observed in younger women with a low 
recurrence score, which may be explained at least partly by the lower event rate among 
younger women and the smaller sample size.
CLINICAL-RISK CATEGORY AND CHEMOTHERAPY BENEFIT
Estimated treatment hazard ratios for 6496 women with an intermediate recurrence score 
who were randomly assigned to endocrine or chemoendocrine therapy are shown in Figure 
2. An estimated hazard ratio of greater than 1 indicates a higher recurrence rate with 
endocrine therapy alone than with chemoendocrine therapy. The level of clinical risk was not 
predictive of chemotherapy benefit in women who had an intermediate recurrence score in 
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the entire population, nor in the 4353 women who were older than 50 years of age or the 
2143 women who were 50 years of age or younger (Fig. 2A). Trends suggested a 
chemotherapy benefit in 476 women who were younger than 50 years of age and had a 
recurrence score of 21 to 25, but these trends did not vary according to clinical risk (Fig. 
2B).
AGE AND CHEMOTHERAPY BENEFIT
We further evaluated chemotherapy benefit as a function of age and menopausal status in 
4338 women with a recurrence score of 16 to 25 (Fig. 1). We found that a chemotherapy 
benefit was most evident at 45 years of age in premenopausal women and waned at younger 
and older ages and with menopause, consistent with an effect due to chemotherapy-induced 
premature menopause. Similar results were found when age (without menopausal status) 
was evaluated as a continuous variable with the use of a natural spline (Fig. S1 in the 
Supplementary Appendix, available at NEJM.org).
EVENT RATES AT 9 YEARS, STRATIFIED ACCORDING TO AGE
Kaplan–Meier estimates of event rates at 9 years, stratified according to age, are shown in 
Table 1. In 6469 women who were older than 50 years of age (two thirds of the trial 
population), the mean (±SE) distant recurrence rate at 9 years was similar, irrespective of use 
or nonuse of chemotherapy, in the cohort with an intermediate recurrence score, regardless 
of whether the clinical risk was low (4.0±0.7% vs. 3.5±0.6%) or high (8.3±1.5% vs. 
9.3±1.9%). Similar findings were noted with respect to invasive disease–free survival.
In 2958 women who were 50 years of age or younger (one third of the trial population), use 
or nonuse of chemotherapy in the group with an intermediate recurrence score was 
associated with similar distant recurrence rates at 9 years if the clinical risk was low 
(3.9+1.0% and 4.7±1.0%, respectively), but distant recurrence rates were lower with the use 
of chemotherapy in the group with high clinical-risk (6.1±1.8% and 12.3±2.4%, 
respectively). Rates of distant recurrence at 9 years were very low among patients who were 
50 years of age or younger who had a low recurrence score, irrespective of clinical-risk 
category (≤1.8±0.9%). Owing to fewer second primary cancers and deaths, rates of invasive 
disease–free survival events were lower among younger women across all recurrence-score 
groups than among women who were older than 50 years of age.
The level of clinical risk also added prognostic information with regard to distant recurrence 
in the 1359 women (both younger and older women) with a high recurrence score who 
received chemo-endocrine therapy. Distant recurrence rates were also low among 589 
women with a high recurrence score and low clinical risk who received chemotherapy 
(7.0±2.4% among older women and 6.2±2.5% among younger women) and were similar to 
those among older women with a low recurrence score and high clinical risk (7.4±3.4%) 
who received endocrine therapy alone. In contrast, among 770 women with a high 
recurrence score and high clinical risk, distant recurrence rates were high among both older 
and younger women despite the use of chemotherapy (19.8±3.9% and 15.2±3.3%, 
respectively).
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ESTIMATION OF CHEMOTHERAPY BENEFIT IN REDUCING DISTANT RECURRENCE AT 9 
YEARS
We previously reported that the estimated absolute reduction in the mean (±SE) rate of 
distant recurrence at 9 years associated with adjuvant chemotherapy among women 50 years 
of age or younger was 1.6±1.9 percentage points in those with a recurrence score of 16 to 20 
and 6.4± 4.9 percentage points in those with a recurrence score of 21 to 25.7 Here, we 
provide estimates of the absolute benefit of chemotherapy, further stratified according to 
clinical risk (Table 2). In 476 women with a recurrence score of 21 to 25, the absolute 
chemotherapy benefit in the subgroup with low clinical risk (6.4±4.9 percentage points) was 
similar to that in the subgroup with high clinical risk (8.7±6.2 percentage points). In the 886 
women with a recurrence score of 16 to 20, there was an estimated chemotherapy benefit 
with high clinical risk (6.5±4.9%) but not with low clinical risk (−0.2±2.1%). The sample 
size was small in some of the subgroups examined; this contributed to higher standard errors 
than estimates for the entire cohort with a recurrence score of 11 to 25.
PROGNOSIS IN WOMEN 50 YEARS OF AGE OR YOUNGER
Among women who were 50 years of age or younger, most of whom were premenopausal 
and treated with tamoxifen alone or followed sequentially with an aromatase inhibitor, the 
distant recurrence rate at 9 years was less than 5% (≤1.8±0.9%) among those with a low 
recurrence score, irrespective of clinical risk, and an intermediate recurrence score with low 
clinical risk (4.7±1.0%) (Table 1). In contrast, the rate of distant recurrence at 9 years 
exceeded 10% among women with high clinical risk and an intermediate recurrence score 
who received endocrine therapy alone (12.3±2.4%) and in those with a high recurrence score 
who received chemoendocrine therapy (15.2±3.3%).
DISCUSSION
The recurrence score based on the 21-gene breast cancer assay provides robust prognostic 
information regarding distant recurrence2 and predicts chemotherapy benefit or lack 
thereof3,4,7; clinicopathological features provide prognostic information that is 
complementary to that of this assay.13-15 The integration of genomic and clinical 
information may provide a more accurate estimation of prognosis for individual patients 
than could be provided by either the genomic or clinical information alone.16 Our analysis 
confirmed that clinical-risk stratification based on tumor size and histologic grade, when 
added to the 21-gene recurrence score, provided prognostic information about recurrence but 
not predictive information regarding chemotherapy benefit.
Although TAILORx showed that endocrine therapy was noninferior to chemoendocrine 
therapy in women with an intermediate recurrence score (a score of 11 to 25),7 we 
performed an exploratory analysis in accordance with recommended guidelines in order to 
determine whether any subgroup might derive some benefit from adjuvant chemotherapy.17 
There was a significant interaction between chemotherapy treatment, age (≤50 vs. >50 
years) or menopausal status, and recurrence score, suggesting a modest but clinically 
meaningful reduction in the rate of distant recurrence with chemotherapy among younger or 
premenopausal women who had a recurrence score of 16 to 25.7 Similar findings were noted 
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in a population-based study indicating a chemotherapy benefit emerging at a recurrence 
score above 15 in women who were 50 years of age or younger and above 25 in women who 
were older than 50 years.18
Adjuvant chemotherapy is associated with nearly twice the reduction in the rate of death 
from breast cancer among women younger than 50 years of age as compared with older 
women1; this has been attributed to a dual effect, which includes a direct cytotoxic effect in 
eradicating micrometastatic disease and an antiestrogenic effect from chemotherapy-induced 
ovarian failure and premature menopause.19,20 The interaction among age, recurrence score, 
and chemotherapy benefit observed in TAILORx is therefore consistent with the greater 
treatment effect of adjuvant chemotherapy in younger women.
Although the potential pitfalls of a subgroup analysis to identify more effective therapies in 
trials with a superiority design have been well described17 and the exploratory analyses 
presented here were not adjusted for multiple comparisons, caution is warranted when 
withdrawing potentially lifesaving therapy on the basis of a noninferiority trial such as 
TAILORx, especially when the findings are biologically plausible and supported by 
population-level data, as described here. Given the incremental benefits observed with 
ovarian suppression plus tamoxifen or an aromatase inhibitor as compared with tamoxifen 
alone in premenopausal women21,22 and the low percentage of premenopausal women who 
received ovarian suppression in TAILORx, it is possible that similar incremental benefits 
observed in younger women who received chemotherapy and had a recurrence score of 16 to 
25 could be achieved with ovarian suppression and an aromatase inhibitor, as observed in 
other trials.21,22 This potential is supported by data indicating that a low-to-midrange 
recurrence score and high estrogen receptor 1 gene (ESR1) RNA expression are predictive 
of benefit from tamoxifen.23,24 For patients who are approaching menopause, a strategy of 
an initial 2-to-5-year course of tamoxifen followed by a switch to an aromatase inhibitor at 
the time of natural menopause is another reasonable approach.25 This may be especially true 
for women with a high ESR1 RNA score obtained as part of the 21-gene assay, which is 
prognostic for late recurrence 5 or more years after diagnosis and thus may identify women 
who are more likely to benefit from continued antiestrogen therapy beyond 5 years. 26
Recurrence rates reflect the underlying recurrence risk, the benefit from adjuvant endocrine 
therapy, and the benefit from adjuvant chemotherapy, the latter of which has little effect on 
nonrecurrence events such as contralateral breast cancer or second primary cancers.27-29 
Estimation of an absolute chemotherapy benefit requires tools to estimate the underlying risk 
of recurrence and the treatment effect of chemotherapy, which may vary in magnitude 
according to tumor biologic features.
When the recurrence score was further stratified according to clinical risk among TAILORx 
patients as described here, there was no evidence of chemotherapy benefit at 9 years in the 
subgroup with a low clinical risk and a recurrence score of 16 to 20, whereas the addition of 
chemotherapy was associated with lower rates of distant recurrence ranging from 
approximately 6 to 8 percentage points among women with a recurrence score of 21 to 25, 
irrespective of clinical risk, and a recurrence score of 16 to 20 with high clinical risk. This 
absolute chemotherapy benefit is similar to the benefit seen in unselected patients with node-
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negative, hormone-receptor–positive breast cancer,30 but it is substantially less than the 
absolute benefit of 25 percentage points observed in patients with a high recurrence score of 
26 to 100.6 The treatment effect associated with chemotherapy in this subgroup is similar to 
that observed with ovarian suppression plus an aromatase inhibitor as compared with 
tamoxifen.21,22 The level of clinical risk also added prognostic information for women with 
a high recurrence score who were receiving chemoendocrine therapy, irrespective of age, 
and thus could be used to identify patients with very high risk for whom testing of new 
therapeutic approaches in clinical trials is warranted.
In conclusion, binary clinical-risk stratification based on tumor size and histologic grade 
added prognostic information to the 21-gene recurrence score, but not prediction of a large 
chemotherapy benefit. The addition of this information enabled more precise identification 
of subgroups of younger women who may derive some benefit from more effective 
antiestrogen therapy than a course of tamoxifen.
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Figure 1. Effect of Clinical Risk on Prognosis in the Entire Population and Stratified According 
to Age.
Hazard ratios and 95% confidence intervals (CIs) for a high versus low clinical risk of 
invasive disease recurrence, second primary cancer, or death and for distant recurrence (a 
hazard ratio of >1 indicates a higher event rate with high clinical risk) are shown. There 
were no distant recurrences among 64 patients in the subgroup who had a high clinical risk 
and a low recurrence score. CIs have not been adjusted for multiple comparisons, and 
inferences drawn from the intervals may not be reproducible. The size of each square 
corresponds to the size of the subgroup; the horizontal lines represent the 95% CI.
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Figure 2. Effect of Clinical Risk on Prediction of Chemotherapy Benefit.
Panel A shows the effect of clinical risk on prediction of chemotherapy benefit in 6496 
women with a recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores 
indicating a worse prognosis or a greater potential benefit from chemotherapy) who were 
randomly assigned to endocrine therapy or chemotherapy plus endocrine (chemoendocrine) 
therapy, and stratified according to age. A total of 4353 women were older than 50 years of 
age, and 2143 women were 50 years of age or younger. Panel B shows the effect of clinical 
risk on prediction of chemotherapy benefit in 2143 women who were 50 years of age or 
younger and had a recurrence score of 11 to 25. Estimated hazard ratios are shown for 
treatment (endocrine vs. chemoendocrine therapy) and 95% CIs for invasive disease–free 
survival and distant recurrence (a hazard ratio >1 indicates that chemoendocrine therapy is 
better). CIs have not been adjusted for multiple comparisons, and inferences drawn from the 
intervals may not be reproducible. The size of each square corresponds to the size of the 
subgroup; the horizontal lines represent the 95% CI.
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Figure 3. Effect of Age and Menopausal Status on Chemotherapy Benefit.
Shown is the effect of age and menopausal status on chemotherapy benefit in 4338 women 
who had a recurrence score of 16 to 25 and were randomly assigned to endocrine therapy or 
chemoendocrine therapy. Estimated treatment hazard ratios (endocrine vs. chemoendocrine 
therapy) and 95% CIs for rates of distant recurrence at 9 years are shown (a hazard ratio >1 
indicates that chemoendocrine therapy is better). Menopause was defined as an age of 60 
years or older; an age of 45 to 59 years with spontaneous cessation of menses for at least 12 
months before registration; an age of 45 to 59 years with cessation of menses for less than 
12 months before registration and a follicle-stimulating hormone (FSH) level in the 
postmenopausal range (or >34.4 IU per liter if the institutional range was not available); 
prior bilateral oophorectomy; or age younger than 60 years with prior hysterectomy without 
bilateral oophorectomy and an FSH level in the postmenopausal range (or >34.4 IU per liter 
if the institutional range was not available). CIs have not been adjusted for multiple 
comparisons, and inferences drawn from the intervals may not be reproducible. The size of 
each square corresponds to the size of the subgroup; the horizontal lines represent the 95% 
CI.
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